Table 2.
Clinical characteristics of patients described in Figure 4a
| MN onset (n = 4) |
MN relapse (n = 2) |
Clinical MN remission (n = 1) |
Secondary MN (n = 2) |
HC (n = 3) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| #1 | #2 | #3 | #4 | #5 | #6 | #7 | #8 | #9 | #10 | #11 | #12 | |
| Age (years) | 37 | 38 | 68 | 28 | 69 | 48 | 63 | 76 | 77 | 25 | 52 | 32 |
| Gender | Male | Male | Male | Male | Male | Male | Male | Male | Male | Female | Male | Female |
| Months after diagnosis | 0 | 0 | 0 | 0 | 15 | 96 | 132 | 12 | 60 | 0 | 0 | 0 |
| Plasma albumin (g/dl) | 1.9 | 1.6 | 2.0 | 2.3 | 2.3 | 4.2 | 4.4 | 3.7 | 3.1 | 4.2 | 4.1 | 3.9 |
| Proteinuria (g/24 h) | 5.6 | 10 | 13.7 | 5.27 | 2.07 | 2.81 | 1 | 14.9 | 8.02 | 0 | 0 | 0 |
| Serum creatinine (mg/dl) | 1.34 | 2.18 | 1.35 | 1.11 | 6.58 | 1.64 | 1.09 | 2.01 | 2.11 | 1.02 | 0.90 | 0.97 |
| Immunosuppression | - | - | - | - | Tac | Tac | - | - | - | - | - | - |
| Serum anti-PLA2R Ab | ||||||||||||
| ELISA (semiquantitive) | + | + | ++ | + | ++ | ++ | ++ | - | - | - | - | - |
| Luminex (MFI) | 9471 | 8307 | 8034 | 4699 | 16,170 | 12588 | 11,005 | 125 | 180 | 75 | 83 | 32 |
| Supernatant anti-PLA22R Ab | ||||||||||||
| PLA2R-specific mBc (MFI) | 1601 | 8209 | 5068 | 1614 | 9765 | 8883 | 364 | 274 | 195 | 60 | 17 | 59 |
| Polyclonal mBc Ab production | 132 | 67 | 96 | 143 | 49 | 129 | 39 | 165 | 52 | 79 | 53 | 90 |
Anti-PLA2R Ab, autoantibodies targeting phospholipase A2 receptor; ELISA, enzyme-linked immunosorbent assay; HC, healthy control; mBC, memory B cell; MN, membranous nephropathy; Tac, tacrolimus.
ELISA results: -, +, and ++ correspond to <20 IU/l, 20 to 150 IU/l, and >150 IU/l, respectively.
All patients were negative for antithrombospondin antibodies.